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Towards the end of 2019, an increasing number of viral pneumonia cases were reported in 25 
Wuhan Hubei Province, China. The causative agent was identified as a coronavirus, which has 26 
been named as the Severe Respiratory Syndrome Coronavirus 2 (SARS-COV-2).  Since the 27 
initial outbreak, the virus has spread rapidly throughout China and other countries leading to 28 
significant human fatalities, resulting in a global pandemic.  Attempts have been initiated to 29 
develop effective approaches that allow rapid detection of viral pathogens to prevent disease 30 
transmission, identify crises associated with health, and wellbeing, set up suitable treatment 31 
modalities, and monitor responses to treatment in order to control the current pandemic. Due to 32 
the high rate of transmission, changing nature of the viral symptoms, diagnosis and treatment 33 
modalities, an up to date comprehensive literature review is needed. This review provides a 34 
comprehensive overview on the current state of knowledge about the viral replication and 35 
pathogenicity, current diagnostic and therapeutic strategies and how they have been applied for 36 
the management of SARS-COV-2. This review will be of interest to scientists and clinicians and 37 
make a significant contribution towards the management of symptoms, development of vaccines 38 










1. INTRODUCTION  47 
Coronaviruses (CoVs) are a positive-sense single-stranded RNA virus that cause diseases in 48 
humans and animals. The human coronaviruses (HCoVs) were first identified as causes of acute 49 
upper respiratory infection (URI) in 1962. Over the past few years, HCoVs have more often been 50 
found to be associated with severe upper and lower respiratory tract infection (RTI). They have 51 
been identified as a main cause of pneumonia in older adults and immunocompromised patients 52 
[1]. Over the last two decades, two highly pathogenic human coronaviruses were identified, 53 
including coronaviruses associated with severe acute respiratory syndrome (SARS-CoV-2) and 54 
the Middle East respiratory syndrome (MERS-CoV) which emerged in different regions of the 55 
world [2]. On 31st December, 2019, a new strain of coronavirus was isolated and named as severe 56 
acute respiratory syndrome coronavirus 2 (SARS-Cov-2) by the International Committee on 57 
Taxonomy of Viruses (ICTV) from patients with pneumonia of unknown aetiology in Wuhan 58 
city, China [3] . On 11th March, 2020, the World Health Organisation (WHO) announced that 59 
COVID-19 is a “public-health emergency of international concern” [4]. 60 
The CoVs belongs to the family Coronaviridae that consist of alpha, beta, delta, and gamma 61 
coronaviruses with large RNA genomes and a unique replication method; the new SARS-CoV-2 62 
was identified as a beta-coronavirus [5]. A number of studies reported that the CoVs have the 63 
largest non-segmented genomes between all RNA viruses with a length of close to 30 kb [6]. 64 
This genome size increase enhances genomic plasticity, thus permitting alteration via mutations 65 
and recombination, resulting in higher genetic diversity and higher chances of cross-species 66 
transmission [7].   67 
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This review aims to provide a comprehensive overview of the current state of knowledge and 68 
research about the mode and mechanisms of transmission, epidemiology, pathogenicity, natural 69 
immunity, genetic basis, diagnostics and therapeutics for COVID-19 diseases.   70 
2. EPIDEMIOLOGY, ORIGIN AND DISEASE TRANSMISSION 71 
The study of evolving epidemiology and spread of COVID-19 pandemic is very important to 72 
acquire ‘timely information to guide intervention policy’ [8]. A recent study has attempted to 73 
depict the changing epidemiology and transmission dynamics of SARS-CoV-2 in mainland 74 
China (outside Hubei province) and reached a conclusion that initial steps taken to stop 75 
transmission of virus might have been effective in slowing down the outbreak [8]. The basic 76 
strategies for the control of ongoing pandemic are dependent on the control measure policies and 77 
human behaviour such as surveillance and isolation, contact tracing, movement restrictions, 78 
social distancing, hand washing and increased awareness in the community [8].  79 
2.1. Ethnicity: The evidence suggests an overrepresentation of American blacks in the USA and 80 
black, Asian, and minority ethnic (BAME) communities in the UK among COVID-19 81 
patients. For example, the first 11 doctors who died in the UK due to COVID-19 were all from 82 
BAME communities [9]. A study in the UK confirmed that a third of COVID-19 patients 83 
admitted to critical care units are from BAME groups.  The death rates (per 100,000)  in the New 84 
York City among Black/African American and Hispanic/Latino persons are 92.3 and 74.3, 85 
respectively, which are much higher in comparison with white (45.2) or Asian (34.5) groups. 86 
Living conditions, genetic predisposition, work circumstances, socio-economic inequalities, 87 
cultural, or lifestyle factors, and underlying health conditions may contribute this morbidity and 88 
mortality [10]. 89 
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2.2. Transmission: The mode of transmission of COVID-19 seems to be similar to that of 90 
SARS-CoV [11]. For example, in 2002, the SARS-CoV emergence resulted from cross- species 91 
transmission from animal to human and spread further via human-to-human transmission.  92 
COVID-19 has now also followed the same pattern with superspreading events (SSEs) resulting 93 
to a pandemic [11].   94 
With the progression of the outbreak, the primary mode of transmission from human to human 95 
has been identified to be through droplets of respiratory mucus secretion, and direct contact. 96 
Droplet transmission occurs when a person talks, sneezes or coughs and the virus is released 97 
from the respiratory secretions. Making direct contact with the mucous membrane of an infected 98 
patient, the droplets tends to transmit the virus. Droplets do not travel more than six feet and do 99 
not linger in the air.  This raises uncertainty regarding the mechanism of transmission perhaps 100 
there are other possible ways by which a person can get infected, for example, by touching 101 
surface or objects that have the virus on it and then touching mouth, nose or eyes [12]. A study 102 
reported the presence of SARS-CoV-2 in faecal and blood swab, further indicating the possibility 103 
of multiply routes of transmission [13]. In the absence of an effective vaccine, the only way to 104 
control and halt this outbreak is to use isolation, frequent hand wash and social distancing as an 105 
effective preventive measure. 106 
2.3. Herd immunity: Infected individuals may develop antibodies to the virus by 14 days 107 
following the onset of symptoms [14]. Preliminary evidence suggests that some of these 108 
antibodies are protective, but this remains to be established. However, it remains unknown 109 
whether all infected patients mount a protective immune response and how long this protective 110 




3. PATHOGENESIS AND REPLICATION  113 
The coronaviruses have the largest genome among positive-stranded RNA viruses and possess 114 
the biggest known replicating RNA molecules.  SARS-CoV-2 replication begins when the viral 115 
spike (S) glycoprotein on the surface of the virus binds to a complementary angiotensin-116 
converting enzyme 2 (ACE2) receptor in the host cell [15]. The ACE2 receptor is expressed in 117 
epithelial cells within a range of organs including lung, kidney and blood vessels [16]. Analysis 118 
of the receptor binding domain (RBD) of the S protein reveals that majority of the amino acid 119 
residues important for receptor binding are conserved among SARS-CoV and SARS-CoV-2, 120 
implying that the SARS-CoV-2 strains use the same host receptor for cell entry [16]. The amino 121 
acid sequences of the ACE2 receptor responsible for binding in farm animals and cats has only a 122 
few exchanges compared with the human receptor, implying that the species barrier for SARS-123 
CoV-2 transmission is limited [17]. However, after binding, there is a membrane fusion between 124 
the virus and the host cell and a protease of the host cell cleaves and activates the receptor- 125 
bounded spike protein allowing the virus to enter the host cell through endocytosis [18]. The 126 
viral genome then enters the cell cytoplasm. The SARS-CoV-2 RNA genome has a 5’ 127 
methylated cap and a 3’ polyadenylated tail, which allows the RNA to attach to the host cell’s 128 
ribosome for translation. The viral genome is replicated with the help of a RNA-dependent RNA 129 
polymerase (RdRp) [19]. RdRp helps to meditate the synthesis of negative-sense genomic RNA 130 
from the positive-sense genomic RNA, which is followed by the replication of positive-sense 131 
genomic RNA from the negative -sense genomic RNA [19]. Additionally, the RdRp also 132 
mediates the transcription of the negative- sense sub-genomic mRNA to the corresponding sub-133 
genomic positive mRNA. The positive genomic RNA becomes the progeny viruses. These RNAs 134 
are translated by the host ribosomes into membrane proteins and accessory proteins and this 135 
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translation process occurs in the endoplasmic reticulum (ER) [20]. The viral structural membrane 136 
proteins are Spike (S), Envelop (E), Membrane (M) and Nucleocapsis (N) proteins. SARS-CoV-137 
2 uses the S-protein to bind on cell surface molecules. However, the S protein also regulates viral 138 
uptake and is regulated by the cell surface-associated transmembrane protease serine protease 2 139 
(TMPRSS2), a key enzyme for S protein cleavage and priming [21]. The protein N binds the 140 
genomic RNA and the protein M is integrated into the membrane of the endoplasmic reticulum 141 
like the envelope protein S. The M proteins, which contain three putative transmembrane 142 
domains then direct protein-protein interactions required for an assemblage of viruses. Following 143 
its binding to the nucleocapsid, the final progeny viruses are  transported  by Golgi vesicles to 144 
the cell membrane and released into the extracellular space through exocytosis (Figure 1) [22]. 145 
4. THE GENDERED IMPACT OF SARS-COV-2 146 
Interestingly, gender-dependent susceptibility patterns have been observed in SARS-CoV-2 147 
infections, with males shown to be more affected than females. One study of 140 patients 148 
diagnosed with SARS-CoV-2 in China, found that a higher percentage of males were critically ill 149 
(67%) in comparison to females [23]. Additionally, a recent report found that out of 1099 150 
patients, 58% of these were men [24]. Similar patterns have also observed previously for both 151 
the SARS-CoV and MERS-CoV infections. Males and females differ in their immunological 152 
response to infectious pathogens, with males often exhibiting a much weaker immune response 153 
in comparison to females [25].  Animal models have previously been utilised to investigate the 154 
difference in susceptibility of each gender to the SARS-CoV virus. A study involving induction 155 
SARS-CoV among mice of different ages found that male mice display enhanced susceptibility 156 
to the SARS-CoV compared with age-matched female mice [26]. Male mice have exhibited 157 
higher titres of the virus, alveolar oedema, increased vascular leakage and prolonged 158 
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inflammatory response which was indicated by elevated levels in pro-inflammatory cytokines 159 
and chemokines [26]. Male mice also have presented with increased levels of inflammatory 160 
monocyte macrophages (IMM) and neutrophils within their lungs, and a reduction in these 161 
inflammatory monocyte macrophages partially protected these mice from SARS [26] .  A reason 162 
for this protective effect is due to the fact that IMMs are a predominant source of both 163 
chemokines and pro-inflammatory cytokines.  Studies have found that elevated levels of 164 
cytokines and chemokines found in mice models, correlated with an increase in the number of 165 
IMMs [27]. Examples of such chemokines and pro-inflammatory cytokines include IL2, IL7, 166 
IL10, CCL2, IP10, MCP1, MIP1α, and TNFα, all of which have shown to contribute to the 167 
lethality of both SARS-CoV and COVID-19 by inducing cytokine storm [28].  168 
Many factors can lead to sex-specific differences in disease outcomes. For example, females sex 169 
hormone oestrogens have been shown to lead to the downregulation of MCP-1 expression during 170 
inflammation and thus inhibit TLR4 mediated NFκβ activation in macrophages, ultimately 171 
resulting in suppression in monocyte-macrophage recruitment. To further support this, 172 
researchers have found that treating female mice with an oestrogen receptor antagonist or 173 
ovariectomy (removal of ovaries) have led to increased mortality for SARS-CoV overall. On the 174 
other hand, treating gonadectomised mice with oestrogen has led to a reduction in chemokines 175 
TNF and CCL2 and showed a protective effect against the influenza virus [29].  Additionally, 176 
when male mice have been treated with a non- steroidal anti-androgen such as flutamide or when 177 
complete removal of testes is performed (gonadectomy), no difference is observed in overall 178 
mortality and morbidity following treatment with SARS-CoV virus. The SARS-CoV virus 179 
however, causes a reduction in serum testosterone levels. This sex-dependent susceptibility has 180 
also been observed in humans and thus identifies the protective effects of oestrogen receptor 181 
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signalling in females as well as suggesting that androgens may not play a role in the pathogenesis 182 
of SARS-CoV [26] . A recent study has also found similar gender-based distribution patterns for 183 
SARS-CoV-2. Jin et al. (2020) have compared the mortality and severity of COVID-19 between 184 
males and females [30]. After observing patient survival and deceased data, the study has 185 
concluded that despite gender distribution being symmetrical in the survival group, there have 186 
been a higher percentage of males in the deceased group and thus concluded that despite both 187 
genders having the same susceptibility, males tend to have higher severity and increased 188 
mortality, an effect that is independent of age and susceptibility [30]. Taken together, the data 189 
indicate that there may be a sex-dependent predisposition that makes males more susceptible to 190 
infectious pathogens (Figure 2) [25,26]. This implies that male gender is a possible risk factor 191 
that can lead to poor outcomes for patients with viral infections such as SARS-CoV-2.  192 
5. CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF COVID-19  193 
The clinical features of COVID-19 are varied and non-specific; disease presentation can range 194 
from asymptomatic to severe pneumonia and death [31].  Yuki et al. provided a classification of 195 
COVID-19 patients based on clinical features/lab investigation which are shown in Table 1 [32]. 196 
The symptoms have been reported to appear after an incubation period between 2-14 days [18]. 197 
The period from the onset of SARS-CoV-2 symptoms to death ranged from 6 to 41 days which is 198 
dependent on the age and the status of the patient’s immune system [18]. The age range affected 199 
was mostly middle-aged patients with a mean age range of 40-59 years and older (> 60 years) 200 
[22,33]. Additionally, studies reported that SARS-CoV-2 disease progressed faster among the 201 
elderly compared with those under the age of 60 years [33]. A research study analysing 1099 202 
laboratory-confirmed patients in Wuhan, has found common clinical features characterised as 203 
mild and moderate symptoms which includes fever (88.7%), cough (67.8%), fatigue (38.1%), 204 
10 
 
sputum production (33.4%), dyspnoea (18.7%), sore throat (13.9%), and headache (13.6%) [33]. 205 
However, some of the patients display gastrointestinal symptoms, with diarrhoea (3.8%) and 206 
vomiting (5.0%). Fever and cough are the most dominant symptoms associated with SAR-CoV-2 207 
and the temperature range is within 39-degree Celsius. About 80% of confirmed SARS-CoV-2 208 
cases have suffered from only mild to moderate forms of the disease, with approximately 12% of 209 
patients being elderly. Asymptomatic carriers of SARS-CoV-2, who presented with a history of 210 
underlying health conditions such as hypertension, chronic obstructive pulmonary disease, 211 
diabetes, cardiovascular disease, have later developed critical illnesses, which manifested as 212 
respiratory failure, septic shock, multiple organ failure and eventually death [18,28].   213 
A comprehensive study reported that SARS-CoV-2 affected children within the age group of 214 
<14, these Paediatric patients < 16 years of age with COVID-19 had  much milder  of fever , 215 
cough, diarrhoea, and moderate case symptoms [34]. Compared to children with SARS, younger 216 
COVID-19 patients also showed less upper respiratory symptoms (e.g. cough and pharyngeal 217 
congestion), but pneumonia was more common (53%) and very similar to the prevalence with 218 
SARS (65%) [35].  219 
However, a study reported that the presence of leukopenia, lymphopenia, and elevated 220 
myocardial enzymes in children with COVID-19 was relative to those of adults [34].  The Study 221 
reported that the abnormal results in paediatric patients were elevated serum creatine kinase MB 222 
(31%), reduced lymphocytes (31%), leukopenia (19%) and enhanced procalcitonin (17%). Some 223 
characteristics differed significantly between the mild and moderate clinical form of COVID-19 224 
as seen in adult patients, including reduced lymphocyte, increased body temperature, high levels 225 
of procalcitonin, D-dimer and creatine kinase MB [35]. 226 
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Patients who met the criteria by exhibiting the symptoms discussed above have undergone 227 
laboratory examinations to test for SARS-CoV-2 and respiratory pathogens. The samples have 228 
been collected as early as symptom onset to obtain higher virus concentration. The laboratory 229 
examination includes a complete blood count, coagulation profile, biochemical test (including 230 
renal and liver function, creatine kinase, lactate dehydrogenase, and electrolytes), collection of 231 
respiratory specimens such as; nasal and pharyngeal swabs, bronchoalveolar lavage fluid, 232 
sputum, or bronchial aspirates,  inflammatory markers such as; serum procalcitonin, and C-233 
reactive protein (CRP) [33]. 234 
6. DIAGNOSTIC TESTING OF SARS-COV-2 235 
Clinical diagnostic testing plays an essential role in the clinical care of patients with infectious 236 
diseases. This includes the detection of specific pathogens and monitoring of patient conditions, 237 
decisive therapy, measuring prognosis, management and disease surveillance. Various laboratory 238 
techniques have been used to confirm the presence or absence of the virus as well as determining 239 
its severity (Table 2). These techniques include molecular testing methods that detect the viral 240 
RNAs such as real-time polymerase chain reaction (RT-PCR) and serological testing methods to 241 
detect antibodies of the SARS-CoV-2 such as immunofluorescent assay (IFA) [37].  242 
RT-PCR, a molecular diagnostic technique is used as a rapid and sensitive method for the 243 
detection of the viral RNAs. This technique has currently been favoured for the detection of 244 
SARS-CoV-2 as it is able to detect viral RNAs at extremely low concentrations in human 245 
plasma. While this technique may detect SARS-CoV-2, it may generate false-positive results. A 246 
rapid reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) assay has been 247 
used, which  extends the capacity of laboratories to process 2.5 time more clinical specimens 248 
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comparative with standard qRT-PCR and hence may provide an opportunity for high-throughput 249 
screening of SARS-CoV-2 [38].  250 
Serological detection of SARS-CoV-2 detects antibodies that are present in the serum samples as 251 
part of the immune response against the virus. Four serological tests including neutralization test, 252 
enzyme-linked immunosorbent assay (ELISA), immunofluorescent assay (IFA), and 253 
immunochromatographic test (ICT) have been used for detecting antibodies to SARS-CoV-2 254 
[39]. The IFA technique analyses the presence of serum IgM and IgG antibodies against SARS-255 
CoV-2 [40]. The IFA serological method produces negative results from samples collected at the 256 
incubation period of the disease but positive results have been observed in samples collected at a 257 
later phase of the disease [40]. The RT-PCR technique has been shown to detect only active 258 
infections and is the most sensitive method of detecting viral RNAs. However, during the 259 
recuperating phase of the disease, detecting antibodies in serum specimens has shown to be more 260 
important than detecting viral RNAs in the case of acute patients and asymptomatic carriers. This 261 
suggests that serological tests can be used as a confirmatory test of the infection. The progress of 262 
developing antibodies in response to an infection is both time and host-dependent. Recent studies 263 
have shown that most patients infected with SARS-CoV-2 seroconvert from 7 to 11 days of post-264 
exposure, while some patients may develop antibodies sooner. Because of this natural delay, 265 
antibody testing  may not always be accurate in cases of acute condition [41].  Detection and 266 
isolation of HCoVs in cell culture is not routinely carried out for diagnostic purposes. This is 267 
mainly due to a lack of permissive cell lines and a lack of viable antisera for culture validation 268 
[42]. However, isolation of the virus in cell cultures is an essential part to provide isolates for 269 
characterization and to developing vaccines and therapeutics for SARS-CoV-2 [43]. These 270 
serological assays have shown to be valuable for the detection of HCoV in different populations 271 
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of patients, including immunocompromised patients with pneumonia, and frail elderly persons 272 
with symptoms of respiratory tract infections (RTI) [44]. Although RT-PCR remains the most 273 
frequent assays to make a conclusive diagnosis of SARS-CoV-2 infection [45], the limited 274 
availability of RT-PCR assay facilities in the early phase of the outbreak has restricted efficient 275 
diagnosis of infected patients with SARS-CoV-2 [46].  276 
Chest CT findings have been recommended as major evidence for clinical diagnosis of SARS-277 
CoV-2 infection diseases [47], and it has been found to be an essential clinical finding to detect 278 
the diseases at an early stage [48]. Moreover, because of the likelihood of a false negative RT-279 
PCR result, the National Health Commission of the People’s Republic of China has encouraged 280 
diagnosis to rely on chest CT alone [49]. Some cases of asymptomatic infection have been 281 
discovered based on abnormal lung findings on CT imaging, which implies that chest CT 282 
imaging should be applied in asymptomatic high-risk individuals with a history of exposure to 283 
patients with SARS-CoV-2 pneumonia to simplify initial identification of the disease [50]. 284 
Researchers have also proposed that CT imaging can be applied as the primary screening tool for 285 
SARS-CoV-2. Moreover, the CT scans play a key role in distinguishing SARS-CoV-2 286 
pneumonia from other respiratory diseases displaying similar clinical signs and symptoms [51], 287 
and hence can be applied as the primary screening tool for SARS-CoV-2. 288 
7. CURRENT AND PROSPECTIVE TREATMENT MODALITIES OF SARS-COV-2 289 
The management and treatment of SARS-CoV-2 is extremely challenging due to asymptomatic 290 
presentations and high infectivity of virus, and lack of effective drugs and vaccines. The Current 291 
and prospective treatment modalities for the treatment of SARS-CoV-2 are summarized in Table 292 
3 and highlighted in the following sections:  293 
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7.1 Life support: The prime approaches are the management of symptoms, signs, care to 294 
maintain essential requirements of life support like oxygen saturation and blood pressure and 295 
treating secondary diseases like other microbial infections and organs failure [52].  296 
7.2. Palliative care: Palliative care management and bereavement supports are essential to 297 
manage COVID-19 patients, caregivers and healthcare workers [53]. Therefore, supports are 298 
needed for complex symptom management, psychological and bereavement support, and 299 
spiritual care [54]. It has been widely suggested to use of opioids as a safe and effective 300 
palliative care intervention for patients with breathlessness and pain [55]. 301 
7.3. Drug development and the use of antiviral drugs: Attempts to develop vaccines against 302 
human corona virus infections, including SARS-CoV and MERS-CoV have been initiated but 303 
due to viral sequence multiplicity the success has been limited [56]. There have been more than 304 
400 clinical trials registered in both the International and Chinese Clinical Trials Registry 305 
Platform to appraise the risk and benefit researched drug for the management of SARS-CoV-2. 306 
These trials aim at either to develop new agents or repurpose established drugs  including 307 
Remdesivir, Oseltamivir, ASC09F (HIV protease inhibitor), Lopinavir, Ritonavir, Darunavir, 308 
and Cobicistat, which are in phase I-III trials [57]. Drugs developed for SARS-CoV and MERS-309 
CoV have also been tested specifically for SARS-CoV-2 [58] . Multiple studies have reported 310 
that Remdesivir (Code No.: GS-5734), a broad-spectrum antiviral agent, which have been found 311 
to be highly effective for the treatment of severe SARS-CoV-2 [59]. Remdesivir in combination 312 
with chloroquine has also been found to be beneficial for  the treatment of SARS-CoV-2  [60]. 313 
The protease inhibitor drugs including Ritonavir, Darunavir and Cobicistat, which were designed 314 
to block HIV viral replication, have been tested. The safety and efficacy of these drugs for the 315 
treatment of SARS-CoV-2 infection are not strong [61] . 316 
15 
 
7.4. Anti-coagulants: As increased thromboembolic events have been observed among 317 
hospitalized patients, association between administration of in-hospital anti-coagulants and 318 
survival in a large cohort (n=2773) of hospitalized patients with COVID-19 has been 319 
investigated. Treatment with anticoagulants has been found to be associated with improved 320 
hospital survival among COVID-19 patients [62]. Therefore, prospective randomized trials are 321 
required to determine whether systemic anti-coagulants offer a survival benefit in hospitalized 322 
patients with COVID-19 [63]. 323 
7.5. Anti-malarial drugs: In early 2020, the chief administrative body of the People’s Republic 324 
of China has reported that chloroquine phosphate, an age-old medicine for the treatment of 325 
malaria, are effective in treating SARS-CoV-2 correlated pneumonia in multicentre clinical 326 
studies [64]. Recently,  the FDA has issued an Emergency Use Authorization (EUA) to allow 327 
drugs such as hydroxychloroquine sulphatesulphate and chloroquine phosphate products to be 328 
tested for certain hospitalized patients with SARS-CoV-2 [65]. The efficacy and safety profile of 329 
chloroquine and hydroxychloroquine have been evaluated over ten hospitals in Wuhan, 330 
Jingzhou, Guangzhou, Beijing, Shanghai, Chongqing, and Ningbo and it has been reported that 331 
chloroquine elicits antiviral potential in the management of the SARS-CoV-2 induced 332 
pneumonia-related complications [66].  Chloroquine has been utilized for over 70 years, and its 333 
safety issues are well documented as safe medicine. During the current deadly pandemic of 334 
COVID-19, chloroquine phosphate has been recommended for treatment SARS-CoV-2 induced 335 
severe respiratory syndrome, if there is no pre-existing contraindication [66]. Chloroquine and 336 
hydroxychloroquine may exert their antiviral activities in part by increasing the pH in host cell 337 
lysosomes which in turn inhibits hydrolytic activity of protease enzymes that are required for 338 
processing of viral glycoprotein during infection [67].   339 
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7.6. Monoclonal antibodies: Additional approaches have been undertaken  either to develop a 340 
vaccine that contains antigen derived from the spike protein which can boost recognition of the 341 
virus by immune cells or to develop monoclonal antibodies that bind to the coronavirus spike 342 
protein and block the interaction with the human cells [68] . For example, a recent study has 343 
reported that the CR3022, a SARS-CoV-specific human monoclonal antibody, is capable of 344 
binding to the RBD of SARS-CoV-2 [69]. The RBD of SARS-CoV-2 has been considered as a 345 
target for developing neutralizing antibodies against both SARS-CoV and MERS-CoV [70]. Pan-346 
coronavirus fusion inhibitors such as EK1 and EK1C4 have been generated, which are capable of 347 
blocking the infection of both SARS-CoV and MERS-CoV. These antibodies and peptides have 348 
the potential for either prophylactic or therapeutic usages [69,71]. 349 
7.7. Convalescent plasma therapy: Recently, convalescent plasma therapy has been 350 
recommended to treat COVID-19 patients [72]. The plasma collected from individuals who have 351 
recovered from COVID-19 contains antibodies to SARS-CoV-2. Although convalescent plasma 352 
has been tested during 2003 SARS-CoV-1, 2009-2010 H1N1 influenza virus, and 2012 MERS-353 
CoV epidemics, its safety and efficacy in COVID-19 patients require further clinical 354 
investigation. 355 
7.8 Type 1 interferons (IFNs): Type I IFNs are antiviral cytokines have a broad antiviral 356 
activity that induce a large range of proteins and can impair viral replication in targeted cells. 357 
Interferon treatments are currently evaluated in clinical trials to treat respiratory diseases e.g. 358 
MERS-CoV and SARS-CoV [73]. Type I IFNs are have also been proposed for the treatment of 359 
COVID-19 [74] . A recent study demonstrated the potential efficacy of human Type I IFN in 360 
suppressing SARS-CoV-2 infection [74]. 361 
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7.9. Antisense oligonucleotides and antisense RNAs: Antisense RNA therapies including 362 
antisense oligonucleotides (ASOs), small RNAs or long non-coding RNAs have been considered 363 
to specifically treat various disorders including viral diseases. Upon entering the ASOs inside the 364 
host cells, they bind to the RNA target, resulting the formation of double-stranded hetero-duplex, 365 
which is then cleaved by cellular RNase H1 [75] . Formivirsen (Vitravene) is the first FDA-366 
approved ASO, which inhibits the expression of major immediate early region 2 of the 367 
cytomegalovirus [76]. The drug has been approved for the treatment of peripheral 368 
cytomegalovirus retinitis in patients with AIDS  [77]. Antisense RNAs have been used in clinical 369 
trials in various disorders including cancers, myopathies and Huntington's disease [78]. As 370 
antisense-based therapies have showed beneficial effects in other diseases and they are easy to 371 
design and cost-effective to manufacture compared with small molecules and antibodies, they 372 
may hold promise for rapid drug development for SARS-CoV infections [79].    373 
7.10. Other Treatment Modalities and Potential Targets: Animal studies have demonstrated 374 
that binding of the coronavirus spike protein to ACE-II down-regulates the receptors and thereby 375 
contributes to severe lung injury [80], which raises the possibility that the delivery of an 376 
excessive soluble form of ACE-II may provide therapeutic intervention.  The soluble ACE-II 377 
may competitively bind with SARS-CoV-2, neutralize the virus and rescue cellular ACE-II for 378 
the protection of the lung from injury. The recombinant human ACE-II seems to be safe, with no 379 
negative hemodynamic effects on healthy subjects [80]. RNA dependent RNA polymerase has 380 
also been targeted for investigational drugs such as Remdesivir and Favipiravir.  Studies have 381 
shown that both agents inhibit RNA dependent RNA polymerase activity and thus may be useful 382 
for the treatment of early or mid-stage of coronavirus diseases [81]. The transmembrane protease 383 
serine 2 which appears to be essential for entry and viral spread has also been considered as a 384 
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potential target [82]. Finally, anti-TMPRSS2 compound such as comostat mesylate has been 385 
tested as a potential anti-coronavirus candidate [80]. 386 
Protein modelling studies on spike protein suggest that SARS-CoV-2 has a strong binding 387 
affinity to human ACE-II receptors. The interactions between ACE-II and spike proteins have 388 
been considered as a therapeutic target in silico modelling, which identified a natural flavonoid 389 
called hesperidin. Hence, a docking-based screening using a quantum mechanical scoring of  390 
chemical libraries of approved drugs may identify chemical agents which can be directly tested 391 
in Phase II-III clinical trials [83]. Recently, steroids have been found to reduce the risk of death 392 
in extremely ill coronavirus patients and increase the survival of one in eight COVID-19 patients 393 
on ventilators [84]. Therefore, steroids such as dexamethasone has become the first life-saving 394 
treatment for seriously ill COVID-19 patients [85].  395 
8. EXPERT OPINION 396 
Despite the widespread investigations on the recently emerged SARS-CoV-2, there are 397 
considerable gaps in our understanding of this virus. Hence, we reviewed extensively different 398 
aspects about the virus including pathogenicity, current diagnostic, epidemiology, transmission 399 
dynamics, and therapeutic strategies and how they have been applied for the management of 400 
SARS-COV-2.  401 
SARS-COV-2 is genetically diverse and has a high tendency to undergo frequent genetic 402 
mutations and gene recombination, which increases the risk of interspecies transmission.  403 
Furthermore, a number of non-structural and auxiliary proteins encoded by this virus seems to 404 
have no known function. Therefore, it is essential to determine the mode of action of these 405 
proteins and their roles in viral pathogenesis and replication. It is equally important to learn 406 
whether this virus has a greater propensity to jump across species and how it has achieved the 407 
non-human to human transmission. This will aid to identify reservoirs of coronaviruses which is 408 
likely to provide novel directions to predict where and when future epidemics may occur.  409 
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Currently, significant efforts have been made to improve the detection systems of SARS-CoV-2. 410 
The diagnosis of SARS-CoV-2 depends on the detection of the coronavirus RNA or antibodies 411 
present in the serum samples. However, each of the methods described in this review has its own 412 
unique advantages and unavoidable disadvantages. The RT-PCR is extensively used for different 413 
types of virus identification with high specificity as well as sensitivity, but its analysis requires 414 
specialised equipment and specialists, which is only conceivable within well-established 415 
laboratories. Adopting a combination of multiple diagnostic approaches could be adapted to 416 
minimise the variables confounded by single detection methods. Analysis of chest CT imaging 417 
findings have been recommended for the diagnosis of SARS-CoV-2 infections. As the CT 418 
imaging technique shows the changing pattern of the images over time of disease onset, it 419 
provides guidance for clinicians to treat patients effectively. Therefore, it is essential to develop 420 
more effective and practical approaches to overcome the shortcomings of the existing methods.  421 
The current management of COVID-19 is based generally on supportive therapy and treatment to 422 
prevent respiratory failure. However, the autopsies of some of the COVID-19 patients are 423 
indicative of a potential role for coagulopathy in this infection. Moreover, many of the COVID-424 
19 patients admitted to the intensive care units have been found to be deficient in vitamin K. So, 425 
it would be worthwhile to investigate the role of vitamin K for countering this infection.    426 
Finally, an exit strategy for a path back to normal life is required, which should involve a multi-427 
prong effort towards development of new treatment and a successful vaccine to protect human 428 
health worldwide and control and halt future outbreaks of SARS‐CoV‐2. Therefore, the bench to 429 
bedside translational research as well as reverse translational works focusing bedside to bench is 430 
very important and would provide the foundation for the development of targeted drugs and 431 
vaccines for SARS-CoV-2 infections. 432 
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Figure 1. The life cycle of SARS-CoV-2 in host cells. SARS-CoV-2 enters target cells through 437 
an endosomal pathway or membrane fusion. The S protein of SARS-CoV-2 binds to cellular 438 
receptor angiotensin-converting enzyme 2 (ACE2) and enters into the host cell by viral fusion. 439 
The virus synthesizes its RNA polymerase that produces viral RNAs, this viral RNA transcribes 440 
smaller sub-genomic positive RNAs that are used to synthesize structural proteins. The proteins 441 
are integrated into the membrane of the Endoplasmic Reticulum (ER) and are assembled in a 442 
nucleocapsid, the progeny viruses are then released from the host cell by exocytosis through 443 
Golgi vesicles and are transmitted through droplets causing infections. 444 
 445 
 446 
Figure 2: Females exhibit greater humoral and cell-mediated immune responses to viral 447 
infections than males. Disparities in the immune responses can be attributed to sex hormones 448 
such as oestrogens and androgens. Sex hormones modify the functions of immune cells by 449 
binding to specific receptors expressed by many immune cells, including lymphocytes, 450 
macrophages, and dendritic cells. This binding stimulates various cell signalling pathways, 451 
resulting in differential production of cytokines and chemokines. After viral exposure, 452 
expression and antigen recognition by TLRs, the induction of the innate immune response, the 453 
activity of antigen presenting cells (APCs) such as dendritic cells and macrophages and 454 
production of inflammatory cytokines (e.g., IFN-β, IFN-γ, and TNF-α) are observed to be much 455 
higher in females than males. The initiation of the adaptive immune response, including the 456 
activation of lymphocytes and the production of antibodies by B cells are also shown to be much 457 
higher in females. The activity of CD4+ and CD8+ T cells along with the expression of antiviral 458 
and proinflammatory genes, many of which have oestrogen response elements within their 459 
promoters are also elucidated to be much higher in females (data not shown). CCL- chemokine 460 
ligand; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; ND, not defined; 461 
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Table 1: Classification of COVID-19 patients based on clinical features/lab investigation 
(adapted from [32]) 
Classifications Clinical features/laboratory investigation 
Asymptomatic COVID-19 nucleic acid test positive. No clinical symptoms and signs. 
Chest imaging – normal. 
Mild Symptoms of acute upper respiratory tract infection: fever, fatigue, 
myalgia, cough, sore throat, runny nose, sneezing) or digestive symptoms 
(nausea, vomiting, abdominal pain, diarrhoea 
Moderate Pneumonia (frequent fever, cough) with no obvious hypoxemia. Chest CT 
with lesions. 
Severe Pneumonia with hypoxemia (SpO2 < 92%) 
Critical Acute respiratory distress syndrome (ARDS), may have shock, 
encephalopathy, myocardial injury, heart failure, coagulation dysfunction 
















Table 2. Recent diagnostic evaluation techniques of SARS-CoV2 
 























SARS-CoV2 RT-PCR Credo Diagnostics  
 




RT-qPCR  3D Medicines  
ePlex 
SARSCoV-2 
Nasopharyngeal swab SARS-CoV2 
RNA 
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SARSCoV-2 







AIT Laboratories Nasal, mid turbinate, 
nasopharyngeal, and 
oropharyngeal swab 

















COVID19 IgG - 
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Finger prick / 
venous blood 
IgG / IgM Lateral flow 
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blood, serum or 
plasma 
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2 ELISA (IgG) 
Serum or plasma IgG Lateral Flow 
Immunoassay 
EUROIMMUN 
US Inc  
Table 3: Examples of drugs that are being trialled to explore their repurposing potential for the treatment of COVID 19 




Company Stage of Trial 
Hydroxychloroquine 
(Plaquenil) 





























 Clinical trial   
ORCHID Study   by 
the Prevention and 
Early Treatment of 
Acute Lung Injury 
(PETAL) Clinical 
Trials Network of the 
National Heart, Lung, 
and Blood Institute 
(NHLBI), part of the 




by FDA for 
unapproved use 
Tocilizumab (Actimera) 
Monoclonal antibody  











binding to both 
soluble and 
membrane-bound 
IL-6 receptors  






Roche Approved for phase 3 




131707-25-0 Currently used for 
the prophylaxis and 
treatment of 
influenza and other 
respiratory viral 
infections 
(Currently licensed in 
Inhibition of 
virus-mediated 
fusion with target 
membrane and a 
resulting block of 
virus entry into 
target cells  
Dermatitis, 
gastrointestinal upset, 




 Trials in China by Dr 
Hu Bo from the 
Huazhong University 
of Science and 
Technology  
China and Russia)  
Sarilumab (Kevzara) 
monoclonal antibody  
1189541-98-7 used in treatment of 
Rheumatoid arthritis 
in adult patients who 
are irresponsive, 
respond inadequately 
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Evaluation of COVid-
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